Corporate
Altimmune Secures FDA Breakthrough Therapy Designation for MASH Drug Pemvidutide
Jan 5
You're signed outSign in or to get full access.
Altimmune (ALT) Earnings Call Transcripts
Browse quarterly earnings call transcripts for Altimmune.
Q3 2025
Nov 6, 2025
Q2 2025
Aug 12, 2025
Q1 2025
May 13, 2025
Q4 2024
Feb 27, 2025
Q3 2024
Nov 12, 2024
Q2 2024
Aug 8, 2024
Q4 2020
Feb 25, 2021
Q3 2020
Nov 10, 2020
Q2 2020
Aug 12, 2020
Q1 2020
May 14, 2020